Biocracked
Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
Research

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

Helix Ward · · 6 min read

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

Burin farko na binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 ba shi ne rage nauyin jiki ba, kuma ba ƙona mai a zahiri ba. An auna adadin mahalarta da suka rasa aƙalla mililita 150 na kitse a ƙarƙashin fata a ƙirji, ta hanyar ultrasound. A makonni 8 bayan ƙarshe‑ƙarshe na magani, 69.6 % (16/23) na mahalarta da suka karɓi CBL‑514 sun kai wannan ragi, yayin da 0 % (0/16) a rukunin placebo (P < .001). Matsalar ita ce adadin mahalarta ya ragu yayin da aka bibiyi lokaci; ƙungiyar da ta bi ka’ida ta ƙunshi mutane 30 kacal, kuma matsakaicin nauyin jiki bai ragu ba.

Ba shawarwarin likita ba ne. CBL‑514 yana cikin gwaje‑gwajen bincike, ba a amince da shi ta FDA ba, kuma ba kari ba ne.

Menene CBL‑514 (kuma menene ba shi ba)

CBL‑514 (ba “CL‑514”) wani ƙaramin sinadari ne da kamfanin Caliway Biopharmaceuticals ke ƙirƙira. Masu bincike na saka shi a cikin ƙashin kitse – a wannan yanayin a ƙirjin – ba a shan shi ba, kuma ba samfurin kasuwa ba ne. Takardun ba su bayyana cikakken tsarin sinadarin ba.

Ana danganta CBL‑514 da allurar lipolysis wadda ke kashe ɗan gunkin kitse (adipocytes). Ba ya ƙara saurin metabolism ko ƙona kalori kai tsaye. An ambaci wasu hujjoji kamar hana DYRK1b da ƙara caspase‑3 da Bax/Bcl‑2, amma waɗannan su ne rahotanni na ƙananan gwaje‑gwaje da ba a wallafa su ba. Binciken mataki na biyu da aka gudanar a baya (Goodman et al., 2022) ya kasance ƙanana kuma ba a yi amfani da placebo ba.

Takarda: Gold M, et al. Aesthetic Surgery Journal. 2025;45(6):611‑620. Open access on PMC | PubMed | DOI | NCT04897412.

Tsarin gwajin a taƙaice

  • Mataki na biyu, rarrabuwa 2:1, single‑blind (masu halarta suna makale; masu bincike da masu ba da tallafi ba su makale ba). An kwatanta da placebo (saline).
  • Cibiyoyi biyar a Amurka da Australia, daga Fabrairu 2022 zuwa Maris 2023.
  • Magani ya ƙunshi allura 25‑50 µL na 2.4 mg/mL (har zuwa 600 mg) a cikin lokutan mako 4, da bibiyar mako 4 da 8 bayan ƙarshe.
  • An auna ƙimar kitse daga kaurin ultrasound a maki 4 a yanki na 300 cm².
  • An raba mahalarta 76 (50 CBL‑514, 26 placebo); an yi magani ga 75 (49 CBL‑514, 26 placebo).

Sakamakon da suka fito (ITT)

≥150 mL ragi (buri na farko)

Lokaci CBL‑514 Placebo P
Makon 4 63.9 % (23/36) 17.4 % (4/23) < .001
Makon 8 69.6 % (16/23) 0 % (0/16) < .001

≥200 mL ragi

  • Makon 4: 58.3 % (21/36) vs 8.7 % (2/23), P < .001.
  • Makon 8: 60.9 % (14/23) vs 0 % (0/16), P < .001.

Exploratory ≥250 mL

44.4 % (16/36) a makon 4 da 52.2 % (12/23) a makon 8 a CBL‑514; babu wani mahalarta placebo da ya kai wannan ragi.

Canjin matsakaicin ƙimar kitse (LS) vs farawa (CBL‑514)

  • Makon 4: ‑199.80 mL
  • Makon 8: ‑209.46 mL
  • Banbanci tsakanin ƙungiyoyi: ‑206.62 mL (95 % CI ‑276.09 zuwa ‑137.16) a makon 4, da ‑216.28 mL (95 % CI ‑288.28 zuwa ‑144.28) a makon 8.

Per‑protocol (n = 30 kacal)

  • Makon 4: ‑314.70 mL
  • Makon 8: ‑279.45 mL
  • Banbanci tsakanin ƙungiyoyi: ‑312.08 mL da ‑276.83 mL. Waɗannan ƙididdigar sun fi girma, amma ƙungiyar PP ƙanana ce kuma an zaɓi ta ne daga waɗanda suka kammala tare da nauyi mai ɗorewa.

Mafi girma guda ɗaya shi ne > 750 mL a wani mahalar CBL‑514 – ba misali na yau da kullum ba.

Alluran zuwa manufa

Daga cikin mahalarta 28 na CBL‑514 da suka kai ≥150 mL, 42.9 % (12/28) sun sami wannan ragi bayan magani ɗaya, 35.7 % (10/28) bayan biyu, wanda ke nuni da 78.6 % a haɗe. A ƙungiyar PP, 44.4 % (8/18) bayan ɗaya, 27.8 % (5/18) bayan biyu.

Gadar nauyin jiki

Wannan ƙimar kitse a yanki ne, ba ƙona kitse gaba ɗaya ba. Matsakaicin nauyin jiki a rukunin CBL‑514 ya ƙaru da +0.45 kg a makon 4 da +0.02 kg a makon 8. A placebo an samu ‑0.76 kg da ‑0.26 kg. Marubutan sun bayyana babu canjin muhimmanci a matsakaicin nauyi ko BMI, kuma sun nuna ragowar kitse a yanki ya faru ko da a wasu mahalarta da suka ƙaru da fiye da 1 kg (ba a nuna cikakken bayanin ba). Bayanai suna nuni da kadanan canjin girman ƙirji, ba da sauƙaƙan jiki ba.

Matsalar adadi

Daga cikin mahalarta 75 da aka yi magani, 38 sun kammala binciken; 37 (49.3 %) ba su kammala ba. Dalilan sun haɗa da:

  • Rasa bin jadawalin (6)
  • Janyewa da kansu (7)
  • Rashin daidaiton nauyi (7)
  • Rashin halarta a lokutan duba (6)
  • Matsalolin lafiya da suka taso sakamakon magani (4)

Wannan dalilin ne ya sa adadin mahalarta CBL‑514 ya ragu daga 36 zuwa 23, kuma placebo daga 23 zuwa 16. Sakamakon 0/16 a makon 8 na placebo yana da ban mamaki, amma yana da alaƙa da ƙananan ƙungiya da ke raguwa. Kashi a makon 8 ya fito ne daga ƙananan mutane, don haka tazarar amincewa (misali 47.08 %–86.79 %) ta fi girma. Marubutan ba su yi gyara don gwaje‑gwaje da yawa ba, kuma girman samfurin gwaji zai iya ƙuntata sahihanci.

Hotuna da ultrasound: abin da ake gani

Takardar ta nuna mata guda biyu, shekaru 49 da 46, waɗanda suka samu ragowar kitse daga 40.85 % zuwa 47.37 % da sauyin nauyi ƙasa da 1 kg. A wacce ke da shekaru 46, kaurin ultrasound a maki 4 ya sauka daga 4.06, 4.20, 3.90, 3.26 cm a farawa zuwa kusan 2 cm ko ƙasa a bibiyoyi biyu. Tsarin 3D ya nuna ragowar a cikin yanki da aka yi magani. Marubutan sun lura da ƙarancin laushin fata a hotunan bayan magani, amma wannan ƙima ne na gani, ba auna ba.

Tsaro: sakamakon TEAE

Kusan kowane mahalarta ya fuskanci TEAE (adverse events) da ya danganci magani, 98‑100 %, ciki har da rukunin placebo. Martani a wurin allura sun haɗa da:

  • Ƙura: 71.4 % (CBL‑514) vs 11.5 % (placebo)
  • Tsaurara: 61.2 % vs 7.7 %
  • Zafi mai tsanani: 18.4 % vs 0 %

Takardar ta ƙara da rabe‑raben tsanani, amfani da maganin zafi, da lokutan warkewa, inda mafi yawan martani suka ɓuya cikin mako 1. Duba cikakken rubutu don ƙididdige cikakken bayani. Masu halarta biyu sun daina shiga saboda tasirin magani. An lura da wani lamari na hyperlipidemia da ake zargin alaka, yayin da wani lamari mai tsanani – metastasis na peritoneal – an ƙayyade ba alaka ba. Ba a samu lalatar fata, kumburi ko raunukan jijiyoyi a wannan rahoton.

Kwatanta da sauran hanyoyin rage kitse (tare da ƙuntatawa)

Marubutan sun ambaci binciken cryolipolysis da suka yi amfani da hanyoyi daban‑daban na aunawa. Wani bincike ya buga ragowar 264.8 mL a ƙirji da flank a makonni 12 bayan zagaye 24, wani kuma ya ba da 39.6 mL a flank a watanni 2 bayan zagaye ɗaya. Sun ce CBL‑514 "yana nuna girma," kuma suka kwatanta sakamako da liposuction. Waɗannan fassarori ne na masu bincike; gwajin CBL‑514 ba ya haɗa gwajin kai‑tsaye da cryolipolysis ko liposuction.

Ƙuntatawa

  • Mataki na biyu tare da lokaci ƙasa (makonni 8 bayan magani)
  • Tsarin single‑blind, tare da masu bincike da ba su makale ba
  • Mai ba da tallafi ya shiga ƙirƙira, nazari, rubutu da yanke shawara don wallafa
  • Yawan fita da ƙananan yawan per‑protocol
  • Demografiya ba su daidaita ba: 94 % mata a rukunin CBL‑514, 86 % farar fata
  • Volume na ultrasound an ƙididdige daga cuboid, ba a auna kitse kai tsaye ba
  • Ba a daidaita don gwaje‑gwaje da yawa ba

Gabaɗaya

CBL‑514 ya rage kimar kitse a ƙarƙashin fata na ƙirji idan aka kwatanta da saline a wannan gwaji, tare da tasiri mai girma da ƙididdiga wadda ta fita fili. Ba ya rage nauyin jiki, kuma shaidar ba ta nuna ƙona mai gaba ɗaya. Har yanzu ana buƙatar gwaje‑gwaje masu girma, dogon lokaci da maimaita su daga masu ba da shawara masu zaman kansu, kuma maganin har yanzu yana cikin matakin bincike.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

HW

Written by

Helix Ward

Helix Ward writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

BY DR. SYNAPSE ·

CBL‑514 wani allura ne da ake bincike don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. A gwajin mataki na 2 da aka gudanar a 2025 tare da mahalarta 76 da aka raba ta bazuwar, an samu raguwar ƙimar kitse da aka auna ta ultrasound idan aka kwatanta da saline, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Ƙididdigar ta gabatar da ƙirar gwajin, ƙimar 2 mg/cm², cikakkun bayanan tasiri da ƙananan lambobi, da hanyar DYRK1b/caspase da kamfanin ya ba da rahoto. An kuma bayyana iyakokin: ƙirar single‑blind, haɗin gwiwar mai tallafa, kusan 49 % rashin kammalawa, gajeren lokaci na bibiyar, da yawan samfurin mata.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

BY DR. SYNAPSE ·

CBL‑514 ba a nuna shi a matsayin maganin narkewar ko kona kitse ba. Da'awar da ake yi ita ce yana hanawa kinase DYRK1b aiki sannan ya tilastawa ƙwayoyin kitse shiga apoptosis ta hanyar caspase‑3 da Bax/Bcl‑2. Hujjar wannan zaɓi ta samo asali ne daga rahotannin kamfanin da ba a wallafa ba a takardun Phase 2a da Phase 2, kuma ba a fayyace takamaiman tsarin sinadarin ba. Gwajin Phase 2 na 2025 ya auna girman kitse da ultrasound, hotuna, da aminci, ba tare da ƙarin bayanai kamar biopsi ko caspase ba. Wannan labarin na nuni da bambanci tsakanin tunanin sel da abin da aka auna a ɗan adam, ciki har da yawan mutuwar mahalarta da tsarin single‑blind.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

BY DR. SYNAPSE ·

Gwaje‑gwajen CBL‑514 su ne gwaje‑gwajen allura da ke binciken tasirin wannan magani, inda adadin 600 mg ke nufin iyakar adadin da ake amfani da shi a kowanne magani a gwaji, ba adadin da za a ci ba. Wannan makala ta bi takaitaccen binciken Phase 2a don tantance ƙimomi (1.2, 1.6, 2.0 mg/cm² a kan 150 cm², n=43, buɗe‑label) kuma ta fayyace asalin adadin 24.96 % da aka ambata. Sannan ta duba Phase 2 da aka gudanar da placebo, inda aka ci gaba da ƙimar 2.0 mg/cm² amma an ninka yanki zuwa 300 cm² tare da iyaka ta 600 mg. Za ku ga dalilin da yasa adadin mg ba za a iya kwatanta su tsakanin gwaje‑gwajen ba, abin da aka rubuta game da tsaro, da kuma dalilin da ya sanya har yanzu ba a amince da shi ba ko ba da shawara ba.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?

BY DR. SYNAPSE ·

CBL‑514 ta wuce gwajin mataki na biyu da aka sarrafa placebo a mujallar *Aesthetic Surgery Journal*, inda marubuta suka ce ta cika manyan manufofin da aka saita. Sai dai wannan bitar na nuna dalilan da ya sa dole a duba ƙirar gwajin sosai: an yi amfani da blind guda ɗaya, masu bincike da mai tallafa ba su da ɓoye, kuma mai tallafa ya shiga ƙirƙira, tantancewa da rubuta sakamakon. Daga cikin mahalarta 75 da aka ba da magani, kawai 38 suka kammala, kuma ƙungiyar da aka yi nazari a kai ta ƙunshi mutane 30 kacal. An dakatar da bibiyar bayan makonni 8, kuma samfurin ya fi yawa mata da fararen fata. Wannan labarin zai fayyace abin da gwajin zai iya tabbatarwa, abin da ba zai iya ba, da dalilin da ya sa ba za a ɗauke shi a matsayin shawara ta likita ko hujja da aka amince da ita ba.

This page is available in